Advertisement

Therapie bronchopulmonaler Erkrankungen

  • P. Entzian

Zusammenfassung

Asthma bronchiale: Eine einheitliche deutsche Leitlinie existiert bisher nicht; auf sehr breitem nationalen Konsens basiert aber die Empfehlung der Deutschen Atemwegsliga [1], die auch unter http://www.atemwegsliga.de zu finden ist. Im Internet können auch unter http://www.ginasthma.com sehr ausführliche englischsprachige Empfehlungen eingesehen werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Wettengel, R., Berdel, D., Hofmann, D., et al: Asthmatherapie bei Kindern und Erwachsenen. Med-Klin. 93 (1998) 639–650CrossRefGoogle Scholar
  2. 2.
    Magnussen, H., Wettengel, R.: Das Peak-flow-Meter. Med Klin 88 (1993) 720–723Google Scholar
  3. 3.
    Warner, J.O., Naspitz, C.K.: Third international pediatric consensus statement on the management of childhood asthma. Pediatr Pulmonol 25 (1998) 1–17PubMedCrossRefGoogle Scholar
  4. 4.
    Pauwels, A.R., Buist, A.S., Calverley, P.M.A, et al.: Global Strategy for the diagnosis, management, and preventions of chronic obstructive pulmonary disease. Am J Resp Crit Care Med 163 (2001) 1256–1276PubMedCrossRefGoogle Scholar
  5. 5.
    Barnes, P.J.: Future advances in COPD therapy. Respiration 68 (2001) 441–448PubMedCrossRefGoogle Scholar
  6. 6.
    Worth, H., Buhl, R., Cegla, U., et al.: Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 56 (2002) 704–738PubMedCrossRefGoogle Scholar
  7. 7.
    Crompton, G.K.: The adult patient’s difficulties with inhalers. Lung 168 Suppl (1990) 658–662Google Scholar
  8. 8.
    Thorsson, L., Edsbäcker, S., Conradson, T.B.: Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 7 (1994) 1839–1844PubMedCrossRefGoogle Scholar
  9. 9.
    Pauwels, R., O’Byrne, P.M. (Hrsg.): Beta 2-agonists in asthma treatment Series Lung Biology in Health and Disease, Vol 106. Marcel Dekker, New York, 1997.Google Scholar
  10. 10.
    Nightingale, J.A., Rogers, D.F., Barnes, P.J.: Comparison of the effects of Salmeterol and Formoterol in patients with severe asthma. Chest 121 (2002) 1401–1406PubMedCrossRefGoogle Scholar
  11. 11.
    Friedman, M., Della Cioppa, G., Kottakis, J.: Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature. Pharmacotherapy 22 (2002) 1129–1139PubMedCrossRefGoogle Scholar
  12. 12.
    Pauwels, R.A., Lofdahl, C.G., Postma, D.S., et al: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997) 1405–1411PubMedCrossRefGoogle Scholar
  13. 13.
    Selroos, O., Estrom, T.: Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilation. Pulm Pharmacol Ther 15 (2002) 175–183PubMedCrossRefGoogle Scholar
  14. 14.
    Davies, B., Brooks, G., Devoy, M.: The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med. 92 (1998) 256–263PubMedCrossRefGoogle Scholar
  15. 15.
    Beeh, K.M., Beier, J., Kornmann, O., et al.: Wirksamkeit und Verträglichkeit einer festen Kombination von Salmeterol/Fluticason in einem einzigen Inhalations-system (Diskus®) bei Patienten mit leicht-bis mittelgradigem Asthma bronchiale. Pneumologie 56 (2002) 91–97PubMedCrossRefGoogle Scholar
  16. 16.
    McDevitt, D.G., Wallace, R.J., Roberts, A., Whitfield, C.R.: The uterine and cardiovascular effects of salbutamol and practolol during labour. Br J Obstet Gynaecol 82 (1975) 442–448PubMedCrossRefGoogle Scholar
  17. 17.
    Nyberg, L.: Pharmakokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis 65 (Suppl 134) (1984) 149–160Google Scholar
  18. 18.
    Heel, R.C., Brogden, R.N., Speight, T.M., Avery, G.S.: Fenoterol: A review of its pharmacological properties and therapeutic efficacy in asthma. Drugs 15 (1978) 3–32PubMedCrossRefGoogle Scholar
  19. 19.
    Walter, S.D., Sackett, D.L., Shannon, H.S., et al: Fenoterol and fatal asthma. Lancet 337 (1991) 186–187PubMedCrossRefGoogle Scholar
  20. 20.
    Crane, J., Pearce, N., Flatt, A., et al: Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1 (1989) 917–922PubMedCrossRefGoogle Scholar
  21. 21.
    Ukena, D., Keller, A., Sybrecht, G.W.: Theophyllin: Neues zu einem bewährten Medikament. Die duale Wirkung in der Therapie des Asthma bronchiale. Med Klin 89 (1994) 668–674Google Scholar
  22. 22.
    Rail, T.W. Drugs used in the treatment of asthma In: Gilman, A.G., Rall, T.W., Nies, A.S., Taylor, P. (Hrsg): Pharmacological basis of therapeutics. Pergamon Press, Elmsford, New York, (1990) 618Google Scholar
  23. 23.
    Kamada, A.K., Szefler, S.J.: How should inhaled glucocorticoids be compared? J Allergy Clin Immunol 99 (1998) 735–737CrossRefGoogle Scholar
  24. 24.
    Boorsma, M., Andersson, N., Larsson, P., Ullman, A.: Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 9 (1996) 1427–1432PubMedCrossRefGoogle Scholar
  25. 25.
    Pedersen, S. Do inhaled corticosteroids inhibit growth in children? State of the art. Am J Respir Crit Care Med. 164 (2001) 521–535PubMedCrossRefGoogle Scholar
  26. 26.
    Toogood, J.H., Lefcoe, N.M., Haines, D.S.M., et al: A graded dose assessment of the efficiency of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 59 (1977) 298–308PubMedCrossRefGoogle Scholar
  27. 27.
    Greenberger, P.A., Patterson, R.: Beclomethasone dipropionate for severe asthma during pregnancy. Ann Intern Med 98 (1983) 478–480PubMedCrossRefGoogle Scholar
  28. 28.
    Chaplin, M.D., Rooks, W., Swenson, E.W., et al: Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 27 (1980) 402–413PubMedCrossRefGoogle Scholar
  29. 29.
    Casaburi, R., Mahler, D.A., Jones, P.W., et al.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir Dis 19 (2002) 217–224CrossRefGoogle Scholar
  30. 30.
    Horwitz, R.I., McGill, K.A., Busse, W.W.: The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 157 (1998) 1363–1371PubMedCrossRefGoogle Scholar
  31. 31.
    Gong, H., Linn W.S., Terrell, S.L., et al.: Antiinflammatory and lung function effects of montelukast in asthmatic volounteers exposed to sulfur dioxide. Chest 119 (2001) 402–408PubMedCrossRefGoogle Scholar
  32. 32.
    Winsel, K.: Antioxidative and entzündungshemmende Eigenschaften von Ambroxol. Pneumologie 46 (1992) 461–475PubMedGoogle Scholar
  33. 33.
    Mezzetti, M., Colombo, L., Marini, M.G., et al: A pharmacokinetc study on pulmonary tropism of ambroxol in patients under thoracic surgery. J Emerg Surg Intens Care 13 (1990) 179–185Google Scholar
  34. 34.
    Janes, J., Routledge, P.A.: Recent developments in the management of paracetamol (acetaminophen) poisoning. Drug safety 7 (1992) 170–177PubMedCrossRefGoogle Scholar
  35. 35.
    Irwin, R.S., Curley, F.J., Bennett, G.M.: Appropriate use of antitussives and protussives. A practical review. Drugs 46 (1993) 80–91PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • P. Entzian

There are no affiliations available

Personalised recommendations